Randomized phase II study comparing paclitaxel with S-1 vs. S-1 as first-line treatment in patients with advanced gastric cancer

Clinical and Translational Oncology

Volumn 15, Issue 10, 2013, Pages 836-842

  Wang, X ^a   Wang, M L ^b   Zhou, L Y ^b   Lu, X Y ^b   Yang, J F ^b   Yu, H G ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b Wuchang Hospital of Wuhan   (China)

Author keywords

Advanced gastric cancer; Efficacy; Paclitaxel; S 1; Safety

Indexed keywords

GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BODY SURFACE; BONE METASTASIS; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HISTOPATHOLOGY; HUMAN; HYPONATREMIA; INFECTION; LACRIMATION; LEUKOPENIA; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERITONEUM METASTASIS; PHASE 2 CLINICAL TRIAL; PIGMENT DISORDER; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; SENSORY NEUROPATHY; SIDE EFFECT; STOMACH CANCER; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VOMITING;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG COMBINATIONS; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; OXONIC ACID; PACLITAXEL; PERITONEAL NEOPLASMS; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE; TEGAFUR; YOUNG ADULT;

EID: 84885185033     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-013-1012-6     Document Type: Article

References (23)

1. Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, Zhou YF, Xiong B, Yonemura Y, Li Y (2011) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol 18:1575-1581
2. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer. J Clin 55:74-108
3. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M (1995) Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71:587-591
4. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M (1993) Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72:37-41
5. Sumpter K, Harper-Wynne C, Cunningham D, Rao S, Tebbutt N, Norman AR, Ward C, Iveson T, Nicolson M, Hickish T et al (2005) Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer 92:1976-1983
6. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24:4991-4997
7. Maehara Y (2003) S-1 in gastric cancer: a comprehensive review. Gastric Cancer 6(Suppl 1):2-8
8. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9:215-221
9. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T (1998) Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34:1715-1720
10. Ajani JA, Faust J, Ikeda K, Yao JC, Anbe H, Carr KL, Houghton M, Urrea P (2005) Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 23:6957-6965
11. Narahara H, Iishi H, Imamura H, Tsuburaya A, Chin K, Imamoto H, Esaki T, Furukawa H, Hamada C, Sakata Y (2011) Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer 14:72-80
12. Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277:665-667
13. Ganansia-Leymarie V, Bischoff P, Bergerat JP, Holl V (2003) Signal transduction pathways of taxanes-induced apoptosis. Curr Med Chem Anticancer Agents 3:291-306
14. Ohtsu A, Boku N, Tamura F, Muro K, Shimada Y, Saigenji K, Akazawa S, Kitajima M, Kanamaru R, Taguchi T (1998) An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol 21:416-419
15. Yamada Y, Shirao K, Ohtsu A, Boku N, Hyodo I, Saitoh H, Miyata Y, Taguchi T (2001) Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol 12:1133-1137
16. Yonemura Y, Endou Y, Bando E, Kuno K, Kawamura T, Kimura M, Shimada T, Miyamoto K, Sasaki T, Sugarbaker PH (2004) Effect of intraperitoneal administration of docetaxel on peritoneal dissemination of gastric cancer. Cancer Lett 210:189-196
17. Chen L, Tian H, Chen J, He ZG, Tao SF, Lokesh G, Peng SY (2005) Surgical management of gastric stump cancer: a report of 37 cases. J Zhejiang Univ Sci B 6:38-42
18. Li XD, Shen H, Jiang JT, Zhang HZ, Zheng X, Shu YQ, Wu CP (2011) Paclitaxel based vs oxaliplatin based regimens for advanced gastric cancer. World J Gastroenterol 17:1082-1087
19. Masuzawa T, Fujiwara Y, Okada K, Nakamura A, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Kurokawa Y, Osawa R et al (2012). Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer. Int J Oncol (epub ahead of print)
20. Uedo N, Narahara H, Ishihara R, Takiuchi H, Goto M, Fujitani K, Hirao M, Tsujinaka T, Imano M, Furukawa H et al (2007) Phase II study of a combination of irinotecan and S-1 in patients with advanced gastric cancer (OGSG0002). Oncology 73:65-71. doi: 10.3892/ijo.2012.1573
21. Fujitani K, Narahara H, Takiuchi H, Tsujinaka T, Satomi E, Gotoh M, Hirao M, Furukawa H, Taguchi T (2005) Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer. Oncology 69:414-420
22. Mochiki E, Ohno T, Kamiyama Y, Aihara R, Haga N, Ojima H, Nakamura J, Ohsawa H, Nakabayashi T, Takeuchi K et al (2006) Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer. Br J Cancer 95:1642-1647
23. Kawabata R, Fujiwara Y, Doki Y, Fujita J, Tsukahara Y, Yamasaki M, Miyata H, Takiguchi S, Monden M (2007) Phase I/II study of a combination of S-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer. Oncology 72:219-225